trending Market Intelligence /marketintelligence/en/news-insights/trending/qyTFHk6kGpRfMS9K8DAU_Q2 content esgSubNav
In This List

Eisai cancer drug shows non-inferiority in phase 3 trial

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Eisai cancer drug shows non-inferiority in phase 3 trial

Eisai Co. Ltd.'s lenvatinib met its primary endpoint in a phase 3 trial comparing the drug as a first-line treatment against Bayer AG and Onyx Pharmaceuticals' sorafenib in patients with unresectable hepatocellular carcinoma, the most common type of liver cancer.

The drug was demonstrated to be just as effective as sorafenib with meaningful improvements in progression-free survival and objective response rate.

The result will support Eisai's regulatory submissions in U.S., Japan, China and Europe this year.